Trial · NCT04277845
Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma
NCT04277845, Phase 2, Unknown, Samsung Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma. Trials, record NCT04277845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04277845
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma
- NCT number
- NCT04277845
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 49 participants, actual
- Lead sponsor
- Samsung Medical Center
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Lenalidomide, Dexamethasone
- First posted
- 2020-02-20
- Last updated
- 2022-09-09
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-Year Progression-free survival (PFS) | 3-years after randomization | The time from randomization into the date of first observation of documented disease progression or death. |
| Secondary | Assessment of response | accessed every each cycle (each cycle is 28days) | Response will be determined by the International Myeloma Working Group Response Criteria every cycle |
| Other | Minimal residual disease (MRD) | at the time when patient get CR or VGPR after 1year administration | Confirmation of MRD negativity |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04277845
GET https://conductscience.org/api/trials/v1/NCT04277845/registered